Actinium Pharmac Stock Price, News & Analysis

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) announced the enhancement of its intellectual property portfolio for its lead candidate, Iomab-B, with patents granted in the EU and Japan. These patents, covering the composition and administration methods of Iomab-B, are expected to be valid through 2036 and 2037. Actinium aims to leverage its patents for aggressive development in targeted conditioning, particularly for bone marrow transplants and cell therapies. The company holds multiple patents globally and enjoys orphan drug designation for Iomab-B, potentially providing market exclusivity.

Actinium Pharmaceuticals (NYSE: ATNM) presented promising data from its pivotal Phase 3 SIERRA trial for Iomab-B at the 2021 SNMMI Annual Meeting. Iomab-B, a radiotherapy targeting CD45, aims to enable potentially curative bone marrow transplant (BMT) for patients with relapsed or refractory acute myeloid leukemia (AML) aged 55 and above. The trial showed a remarkable 100% BMT and engraftment rate in the Iomab-B group, while only 18% in the control arm. With 75% patient enrollment completed, the results highlight Iomab-B's potential to transform treatment outcomes in this challenging patient population.

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) presented safety data from the Phase 3 SIERRA trial of Iomab-B for relapsed or refractory Acute Myeloid Leukemia at the 2021 SNMMI Annual Meeting. The study involved 113 patients, demonstrating lower rates of sepsis, febrile neutropenia, mucositis, and non-relapse transplant-related mortality compared to traditional therapies. Iomab-B's targeted delivery system aims to minimize side effects while preparing patients for bone marrow transplants. With 75% enrollment complete, Actinium anticipates further data presentations in the future.

Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced acceptance of three abstracts from its pivotal Phase 3 SIERRA trial for Iomab-B at the SNMMI 2021 Annual Meeting, scheduled for June 11-14. Iomab-B targets conditioning prior to bone marrow transplantation for patients aged 55 and over with relapsed or refractory acute myeloid leukemia. The trial reports a 25%, 50%, and 75% enrollment, showcasing Iomab-B's potential as a best-in-class treatment with low transplant-related mortality. The findings emphasize the significance of Iomab-B in improving BMT outcomes.

Actinium Pharmaceuticals (NYSE: ATNM) will present its Iomab-ACT program at the Cell & Gene Meeting on the Mediterranean from April 6-9, 2021. Iomab-ACT is a lower-dose radiation treatment aimed at achieving lymphodepletion before CAR-T therapies and gene therapies. The company collaborates with Memorial Sloan Kettering Cancer Center for a pioneering trial targeting CD19 CAR T-cell therapy, and with UC Davis for anti-HIV stem cell gene therapy. Actinium continues to advance its clinical pipeline focusing on improving patient outcomes in hematologic malignancies.

Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced the completion of patient enrollment in the second dose cohort of the Phase 1 portion of its Actimab-A and venetoclax combination trial for relapsed/refractory Acute Myeloid Leukemia (r/r AML). This trial aims to determine the maximum tolerable dose of Actimab-A before progressing to Phase 2. Initial results from the first dose cohort indicated significant patient responses, with one complete remission and another partial response noted. Actinium plans to present further data in the latter half of 2021.

Actinium Pharmaceuticals (NYSE: ATNM) announced the commencement of patient enrollment in a Phase 1 study of Iomab-ACT for targeted conditioning before treatment with Memorial Sloan Kettering's CD19 CAR T-cell therapy. Iomab-ACT, a low-dose version of the Phase 3 candidate Iomab-B, aims to reduce toxicities associated with CAR T-cell therapy. The study, supported by NIH grant funding, follows promising preclinical data and previous clinical observations. Initial patient treatments are anticipated in Q2 2021, with proof-of-concept data expected later in the year.

Actinium Pharmaceuticals (NYSE: ATNM) announced that preclinical data for its Ac-225-based CD45-targeted conditioning agent has been accepted for presentation at the AACR 2021 annual meeting from April 10-15, 2021. This data indicates selective accumulation in immune cell organs, demonstrating a dose-dependent response for both low and high doses, applicable for therapies like CAR-T and bone marrow transplants. Actinium's Iomab-B remains in pivotal Phase 3 trials while they leverage their Antibody Warhead Enabling technology for enhanced therapeutic options.

Actinium Pharmaceuticals (NYSE: ATNM) announced Mark Kubik's appointment as Chief Business Officer, effective immediately. Kubik, formerly with OncoImmune, will lead business development, focusing on partnerships and advancing Actinium's AWE technology and pipeline of antibody radiation conjugates (ARCs). His extensive background includes a successful acquisition of OncoImmune by Merck for $425 million. Actinium expects significant developments in 2021, including completing SIERRA enrollment and proof of concept data across multiple clinical programs, enhancing its research capabilities and portfolio.